NDRG1‐Driven Lactate Accumulation Promotes Lung Adenocarcinoma Progression Through the Induction of an Immunosuppressive Microenvironment
Gujie Wu, Hongxia Cheng, Jiacheng Yin, Yuansheng Zheng, Haochun Shi, Binyang Pan, Ming Li, Mengnan Zhao, Jiaqi Liang, Yunyi Bian, Guangyao Shan, Guoshu Bi, Weigang Guo, Lin Wang, Yiwei Huang
Abstract
Abstract Lung adenocarcinoma (LUAD) is a leading cause of cancer‐related mortality, with the tumor microenvironment (TME) playing a critical role in its progression. Metabolic reprogramming, particularly lactate accumulation, drives immune suppression within the TME. Utilizing single‐cell RNA sequencing (scRNA‐seq) of 30 LUAD samples, genome‐wide association studies (GWAS) involving 29,863 patients and 55,586 controls, and clinical data from 220 LUAD patients, we identified N‐Myc downstream‐regulated gene 1 (NDRG1) as a key pathogenic gene in LUAD, strongly associated with tumor progression and poor prognosis. Mechanistic studies revealed that NDRG1 stabilizes lactate dehydrogenase A (LDHA) by inhibiting its ubiquitination, thereby enhancing glycolysis and promoting lactate accumulation. This process fosters immune suppression by inducing M2 macrophage polarization, impairing CD8 + T cell function, and upregulating immunosuppressive genes. Furthermore, histone H3K18 lactylation in macrophages exacerbates this immunosuppressive state. Clinically, elevated NDRG1 expression correlates with increased PD‐L1 levels, a higher abundance of immunosuppressive macrophages, and reduced CD8 + T cell infiltration, contributing to immunotherapy resistance. Conversely, low NDRG1 expression is associated with enhanced CD8 + T cell infiltration and improved therapeutic outcomes. Preclinical studies demonstrated targeting NDRG1 suppresses tumor growth, alleviates immune suppression, and boosts anti‐PD‐L1 efficacy. These findings establish NDRG1 as a critical LUAD regulator and a promising immunotherapy target.